review
provid
insight
variou
opportun
vaccin
intervent
analysi
strategi
vaccin
develop
vaccin
abil
modul
immun
respons
result
ration
vaccin
design
addit
wider
aspect
consid
biotechnolog
advanc
advanc
immunolog
understand
hostpathogen
interact
key
question
address
research
understand
reach
new
echelon
vaccin
develop
ration
design
goal
vaccin
induct
appropri
effect
immun
respons
precis
constitut
effect
immun
respons
mani
diseas
still
unclear
specif
level
antibodi
consid
protect
vaccin
efficaci
vaccin
hepat
diphtheria
tetanu
exampl
antihepat
surfac
antigen
antibodi
level
miuml
antidiphtheria
antibodi
level
miuml
antitetanu
antibodi
level
miuml
quot
protect
level
antibodi
human
howev
mani
diseas
correl
efficaci
less
obviou
yet
agre
definit
perceiv
need
acut
awar
requir
effect
vaccin
infecti
agent
pathogen
ancient
reemerg
new
yet
opportun
manipul
immun
respons
offer
potenti
prevent
treatment
far
larger
divers
diseas
immunomodul
cancer
allergi
autoimmun
diseas
also
consid
recent
develop
brought
vaccin
infecti
diseas
forefront
scientif
commun
wake
call
came
sar
sever
acut
respiratori
syndrom
undoubtedli
fuell
present
fear
flu
pandem
spanish
flu
pandem
provid
extrem
histor
preced
caus
estim
million
death
infect
one
billion
peopl
worldwid
impact
outbreak
today
seriou
concern
capac
exist
infrastructur
limit
fatal
provid
suitabl
healthcar
although
develop
suitabl
vaccin
take
minimum
six
month
organ
prepar
scenario
could
provid
major
weapon
ultim
contain
catastroph
latest
polio
outbreak
look
set
delay
long
hope
erad
diseas
uk
substitut
live
oral
polio
vaccin
inact
vaccin
provid
step
toward
safe
cessat
polio
vaccin
time
right
live
vaccin
capac
gener
infecti
polio
viru
mutat
alter
immunolog
properti
mutant
present
concern
viru
spread
immun
well
nonimmun
popul
taken
whole
vaccin
research
develop
encompass
wide
divers
potenti
applic
development
strategi
opportun
ongo
elucid
immunolog
mechan
pathogen
recognit
adjuv
action
well
knowledg
pathogen
mediat
mechan
immun
evas
gene
express
transform
understand
immunolog
diseas
recent
year
complex
increasingli
focuss
environ
vaccin
develop
opportun
new
solut
vaccin
design
new
refin
approach
succeed
convent
approach
appear
fail
sever
reason
bacillu
bcg
vaccin
tuberculosi
tb
perceiv
ineffect
includ
manipul
immun
respons
virul
tb
interestingli
variat
propag
strain
bcg
case
tb
recent
literatur
correl
product
interleukin
splice
variant
antagonist
propens
latent
infect
host
succumb
activ
tuberculosi
product
correl
control
diseas
focu
type
immun
respons
need
engend
protect
tb
seem
orient
convincingli
toward
suppress
long
stand
dogma
advoc
import
type
cytokin
interferon
gamma
tb
resist
case
hiv
one
hiv
candid
vaccin
complet
clinic
trial
phase
ii
iii
year
epidem
phase
iii
trial
base
use
recombin
envelop
protein
aim
evok
viru
neutral
antibodi
howev
result
disappoint
current
avail
vaccin
mostli
effect
viral
diseas
normal
clear
natur
infect
influenza
smallpox
polio
three
virus
measl
mump
rubella
mmr
immunis
hiv
common
epsteinbarr
viru
cytomegaloviru
hepat
b
c
herp
simplex
viru
normal
establish
chronic
infect
opinion
divid
type
immun
respons
requir
control
hiv
neutral
antibodi
might
effici
block
viru
particl
poorli
effect
cellassoci
viru
wherea
cytotox
lymphocyt
ctl
effect
viral
infect
cell
free
viru
particl
latent
infect
facilit
immun
evas
rate
mutat
inher
hiv
also
facilit
evas
escap
respond
cell
promis
vaccin
strategi
like
depend
upon
highli
conserv
epitop
upon
vaccin
strategi
induc
potent
immun
respons
capabl
drive
cytotox
produc
broadli
effect
neutral
antibodi
allerg
autoimmun
diseas
repres
undesir
hypersensit
immun
respons
normal
harmless
environment
antigen
case
allergi
normal
toler
selfprotein
case
autoimmun
understand
pathogenesi
allerg
autoimmun
diseas
led
sever
propos
associ
caus
diseas
shown
highaffin
cell
outcompet
loweraffin
cell
respons
antigen
vivo
competit
cell
provid
basi
argument
maintain
balanc
peripher
immun
system
might
also
side
effect
normal
competit
share
resourc
within
intact
immun
system
mechan
propos
respons
increas
occurr
diseas
hypersensit
normal
passiv
control
expans
immun
cell
specif
preval
infecti
agent
autoimmun
strong
associ
exposur
crossreact
protein
gene
encod
major
histocompat
complex
mhc
strongli
associ
autoimmun
diseas
markedli
less
allergi
allergi
autoimmun
thought
differ
virtu
regul
central
peripher
toler
genet
predisposit
environment
exposur
believ
play
key
role
develop
asthma
atopi
signific
increas
incid
disord
thought
provid
evid
involv
variou
environment
factor
especi
develop
countri
rational
immunolog
therapeut
intervent
strongli
support
present
lack
cur
treatment
autoimmun
allerg
disord
grow
unmet
need
larg
palli
treatment
without
problem
evid
patholog
associ
allergi
autoimmun
revers
provid
transient
longterm
resolut
diseas
well
success
specif
allergen
immunotherapi
subcutan
sublingu
administr
sensit
protein
modifi
immun
reduc
allergen
sensit
serolog
identif
antigen
recombin
express
clone
led
identif
multitud
new
tumour
antigen
thought
paraneoplast
neurolog
disord
neurolog
disord
remot
site
malign
neoplasm
metastas
immun
mediat
cite
evid
involv
specif
immun
respons
cancer
suppress
inde
failur
find
relev
antigen
cancer
patient
prompt
search
second
cancer
wwwdrugdiscoverytodaycom
immunotherapi
recent
achiev
much
interest
possibl
addit
chemotherapeut
treatment
could
open
new
innov
avenu
clinic
trial
effect
chemotherapi
schistosoma
mansoni
praziquantel
depend
presenc
antibodi
recogn
schistosom
glycoprotein
epitop
anoth
interest
approach
therapeut
vaccin
cancer
target
antiapoptot
molecul
infecti
agent
implic
caus
cancer
contribut
varieti
malign
worldwid
major
player
role
shown
tabl
account
sever
common
malign
malign
around
globe
agent
offer
increas
potenti
prevent
cancer
prophylact
vaccin
administr
antisera
treatment
snake
venom
date
back
work
albert
calmett
although
articl
larg
focus
activ
immunis
gener
host
antibodi
host
immun
system
strategi
passiv
immunis
worth
consider
epitop
identifi
use
modern
molecular
biolog
techniqu
might
target
use
passiv
administ
monoclon
antibodi
exampl
immunotherapi
use
monoclon
antibodi
campath
alemtuzumab
manufactur
genzym
treatment
bcell
chronic
lymphocyt
leukaemia
rituxan
rituximab
chimer
murinehuman
monoclon
antibodi
target
antigen
found
surfac
normal
malign
b
lymphocyt
use
treatment
nonhodgkin
lymphoma
strategi
restrict
cancer
exampl
remicad
chimer
monoclon
antibodi
specif
tumour
necrosi
factor
use
treatment
autoimmun
diseas
implement
ration
design
first
evid
pasteur
reproduc
manufactur
attenu
cultur
chicken
cholera
vaccin
therebi
routin
prevent
cholera
vaccin
chicken
extrapol
strategi
anthrax
vaccin
livestock
success
signific
econom
benefit
despit
elucid
attenu
vaccin
strategi
rabi
inactiv
wholeorgan
vaccin
toward
end
nineteenth
centuri
nt
cellcultur
revolut
attenu
viral
vaccin
realli
took
togeth
isol
use
extract
subunit
infecti
agent
pasteur
approach
attenu
inactiv
still
today
provid
two
pole
vaccin
technolog
chronolog
import
develop
achiev
vaccin
research
implement
shown
figur
recent
develop
vaccin
technolog
applic
includ
combin
vaccin
new
adjuv
deliveri
system
revers
vaccinolog
vaccin
noninfecti
diseas
histori
vaccin
develop
much
relat
technolog
advanc
subunit
vaccin
produc
bulk
safe
reproduc
use
recombin
dna
technolog
much
research
alreadi
accomplish
develop
suitabl
carrier
system
abl
engend
enhanc
immun
respons
entrap
peptid
protein
epitop
identif
potenti
use
antigen
greatli
facilit
improv
molecular
biolog
techniqu
microarray
technolog
discuss
elucid
full
potenti
might
reli
develop
effect
deliveri
system
adjuv
mani
adjuv
base
microbi
compon
other
tradit
aluminium
salt
recent
emuls
surfact
base
formul
exploit
differ
mechan
action
particul
deliveri
mediat
polym
often
poli
lactidecoglycolid
microparticl
immunostimulatori
complex
liposom
virosom
possibl
advantag
particul
deliveri
antigen
coadjuv
deliv
cell
particul
excel
potenti
target
cell
immun
system
extens
divers
adjuv
deliveri
system
comprehens
review
elsewher
review
appropri
focu
applic
aspect
technolog
million
dose
influenza
vaccin
need
annual
worldwid
requir
million
chicken
egg
six
month
develop
cellcultur
technolog
could
replac
eggbas
manufactur
process
might
facilit
faster
product
muchhigh
antigen
yield
live
vaccin
gener
possess
natur
adjuv
capabl
built
evolv
abil
immun
system
recogn
mani
facet
potenti
danger
microb
contribut
immeasur
control
diseas
although
live
vaccin
might
undesir
characterist
mutat
polio
viru
persist
virus
varicella
zoster
viru
use
inde
remain
abl
significantli
reduc
impact
associ
diseas
virus
bacteria
carrier
heterolog
antigen
gene
receiv
consider
attent
previou
decad
gener
auxotroph
mutant
well
use
replic
incompet
vector
reassort
virus
gener
addit
rna
segment
virus
segment
genom
influenza
rotaviru
indic
potenti
inher
effici
type
vaccin
interest
util
viral
replic
selfrepl
rna
vector
encod
model
antigen
shown
protect
mice
subsequ
tumour
challeng
colon
carcinoma
cell
engin
express
also
shown
effect
induc
apoptosi
transduc
cell
observ
apoptosi
also
facilit
enhanc
uptak
dendrit
cell
like
mediat
presenc
doublestrand
rna
replic
viral
deriv
genom
doublestrand
rna
recogn
tolllik
receptor
tlr
bind
differ
tlr
recogn
differ
surfac
intracellular
compon
microorgan
interact
tlr
microbi
compon
trigger
activ
innat
immun
system
wwwdrugdiscoverytodaycom
initi
acquir
immun
elucid
pathway
shed
light
mechan
adjuv
action
provid
basi
inclus
potent
agent
analogu
vaccin
design
import
consid
classifi
view
ration
design
context
vaccin
pictur
spring
mind
rapid
analysi
pathogen
identif
alloc
immunolog
interact
specif
gene
well
gener
superimpos
choreographi
infect
diseas
process
result
identif
credibl
candid
target
antigen
follow
appropri
formul
adjuv
deliveri
system
might
elicit
immun
respons
type
magnitud
predict
provid
protect
therapeut
action
truth
still
far
idyl
recent
articl
intim
minor
contribut
knowledg
immunolog
develop
vaccin
howev
develop
improv
largescal
cellular
immun
techniqu
analysi
immun
respons
elispot
cytokin
induct
tetram
stain
peptid
specif
ctl
along
analysi
immunolog
basi
efficaci
success
vaccin
facilit
role
immunolog
predict
appropri
context
antigen
deliveri
extens
characteris
adjuv
action
potenti
target
desir
immun
respons
exploit
knowledg
key
ration
vaccin
design
interact
differ
element
involv
ration
vaccin
design
outlin
figur
use
microarray
technolog
allow
identif
virul
gene
vaccin
target
one
power
tool
studi
transcriptom
complet
set
transcript
organ
inde
conjunct
proteom
compar
genom
analysi
interpret
wholegenom
sequenc
bioinformat
genom
mine
use
assign
put
gene
function
open
read
frame
basi
homolog
known
protein
systemat
identif
potenti
antigen
pathogen
use
inform
without
need
cultiv
pathogen
term
revers
vaccinolog
repres
signific
departur
toward
idyl
ration
vaccin
design
describ
least
term
dissect
potenti
pathogenrel
antigen
knowledg
pathogen
interact
infect
provid
invalu
insight
potenti
success
target
vaccin
exampl
knowledg
gene
express
mycobacterium
tuberculosi
enabl
us
see
vaccin
base
earli
secret
protein
gener
effect
preexposur
vaccin
help
us
predict
effect
postexposur
vaccin
util
dormanc
induc
protein
heat
shock
protein
hspx
case
hiv
implic
lipid
raft
viral
entri
bud
process
might
provid
rational
evalu
peptid
base
highli
conserv
bind
domain
glycoprotein
candid
vaccin
formul
encouragingli
result
peptid
capabl
elicit
neutral
antibodi
respons
abl
inhibit
differ
clade
thought
poor
abil
specif
antibodi
neutral
primari
isol
due
least
part
steric
factor
limit
antibodi
access
epitop
import
factor
ration
design
vaccin
cyclic
gener
knowledg
level
involv
factor
depend
aetiolog
agent
diseas
exampl
level
protect
requir
popul
herd
immun
differ
could
allow
theoret
flexibl
vaccin
efficacyth
applic
molecular
biolog
techniqu
crucial
identif
new
candid
antigen
subsequ
determin
vaccin
efficaci
use
adjuv
feed
knowledg
back
correl
protect
term
immunolog
markersthi
knowledg
use
choic
appropri
adjuv
formulationth
key
implic
project
schemat
greatest
challeng
vaccin
develop
cyclic
gener
knowledg
provid
strong
role
ration
design
protect
therapeut
includ
revers
vaccinolog
associ
technolog
correl
protect
immunolog
marker
defin
protect
antigen
antibodi
bind
domain
rare
mani
hiv
infect
individu
possibl
presenc
hypervari
immunodomin
epitop
locat
lack
exposur
conserv
region
propos
opportun
vaccin
hiv
tb
summar
figur
rational
elicit
success
neutral
antibodi
hiv
centr
upon
increas
immunogen
poorli
immunogen
peptid
modif
andor
remov
hypervari
region
mimick
viral
conform
chang
one
hottest
area
interest
regard
new
vaccin
develop
surround
phase
iii
efficaci
trial
prospect
licensur
two
vaccin
human
papillomaviru
hpv
vaccin
one
merck
one
gsk
effect
vaccin
cervic
cancer
unequivoc
link
common
viru
rare
caus
seriou
diseas
cervic
cancer
found
credenc
long
ago
product
vaccin
merck
vaccin
produc
yeast
administ
aluminium
adjuv
gsk
vaccin
baculoviru
adjuv
aluminium
bacteri
lipid
alreadi
approv
use
europ
basi
work
elucid
product
selfassembl
viruslik
particl
hpv
outer
coat
protein
variou
cell
type
vaccin
neisseria
meningitidi
serogroup
develop
use
tradit
approach
howev
group
b
meningococcu
repres
particular
challeng
sequenc
variat
surfac
protein
crossreact
capsular
polysaccharid
propos
opportun
vaccin
tb
hiv
case
util
adjuv
capabl
drive
requir
type
immun
respons
usedthi
base
current
understand
tlr
interact
studi
manipul
understand
might
also
serv
elucid
complex
interact
infect
diseas
accord
recent
model
antigen
specif
cell
cell
cell
restrict
cell
particip
protect
tuberculosi
infect
respons
antigen
present
macrophag
dendrit
cell
dc
probabl
also
involv
crossprim
mycobacteri
antigen
transfer
infect
dc
unlik
induct
product
induc
nitric
oxid
synthas
alon
enough
control
tb
infect
evid
indic
might
anoth
role
cellsth
develop
preand
postexposur
vaccin
like
requir
antigen
express
tuberculosi
preand
postexposur
condit
respect
interestingli
nonpolymorph
restrict
cell
thought
evolv
result
prolong
interact
mycobacteria
indic
extent
impact
mycobacteria
mammalian
host
b
vaccin
hiv
seem
increasingli
like
strategi
depend
upon
highli
conserv
epitop
vaccin
strategi
induc
potent
immun
respons
capabl
drive
cytotox
well
broadli
reactiv
highli
effect
neutral
antibodiestarget
antigen
might
probabl
differ
strategi
figur
adapt
permiss
ref
adsorpt
antigen
maintain
conform
integr
host
polysial
acid
case
revers
vaccinolog
convincingli
appli
overcom
problem
altern
mean
screen
dna
fragment
discard
like
cytoplasm
protein
sequenc
known
neisseria
antigen
extens
clone
express
identifi
candid
gene
allow
select
antigen
found
offer
signific
potenti
protect
group
b
meningococcu
also
facilit
crossprotect
heterolog
strain
also
worth
mention
techniqu
molecular
breed
gene
shuffl
reassembl
chimer
gene
creat
select
homolog
gene
sequenc
relat
sequenc
denatur
anneal
subsequ
extend
effect
selfprim
polymeras
chain
reaction
pcr
take
advantag
crossov
delet
insert
invers
point
mutat
occur
natur
evolut
henc
term
molecular
breed
protein
gene
enhanc
activ
select
inclus
round
molecular
breed
proven
applic
gener
enzym
markedli
enhanc
activ
enhanc
function
divers
rang
protein
green
fluoresc
protein
techniqu
thought
superior
method
employ
random
mutagenesi
errorpron
pcr
henc
phrase
ration
basi
irrat
design
screen
candid
antigen
gene
necessarili
expens
term
resourc
time
compar
exampl
screen
enzym
potenti
note
relev
allergi
vaccin
preexist
immun
therapeut
target
screen
allergen
variant
might
somewhat
practic
bring
togeth
development
strategi
knowledg
glean
host
pathogen
interact
repres
highli
evolv
design
strategi
although
individu
molecular
biolog
techniqu
appear
someth
contribut
vaccin
develop
holist
applic
combin
approach
closest
premedit
plan
ration
vaccin
design
pathogen
streptococcu
pneumonia
porphyromona
gingivali
staphylococcu
aureu
chlamydia
pneumonia
bacillu
anthraci
investig
use
bioinformat
techniqu
context
revers
vaccinolog
continu
interest
result
term
antigen
identif
nation
institut
allergi
infecti
diseas
niaid
recent
announc
initi
largescal
antibodi
cell
epitop
discoveri
program
util
complementari
method
epitop
discoveri
design
identifi
immun
epitop
select
infecti
agent
make
inform
freeli
avail
scientist
worldwid
immun
epitop
databas
analysi
resourc
iedb
current
develop
recent
discoveri
result
wealth
option
consid
term
vaccin
design
product
mechan
adjuv
action
elucid
pattern
recognit
receptor
includ
tolllik
receptor
scaveng
receptor
mannos
receptor
becom
increasingli
well
defin
intracellular
event
relat
activ
transcript
factor
express
inflammatori
cytokin
shed
light
ligand
adjuv
bind
pattern
recognit
receptor
mediat
immunolog
action
abil
infecti
agent
induc
rapid
innat
immun
respons
molecular
pattern
provid
basi
adjuv
immunotherapi
cancer
studi
recent
work
examin
adjuv
activ
bcg
cellwal
skeleton
peptidoglycan
lipopolysaccharid
induct
gene
dendrit
cell
possibl
help
achiev
definit
effici
effector
output
minim
toxic
easier
safer
product
vaccin
vaccin
compon
facilit
modern
biolog
techniqu
underpin
ration
approach
integr
part
ration
design
vaccin
extens
knowledg
immunolog
mechan
host
pathogen
interact
abl
contribut
design
effect
vaccin
addit
elucid
mechan
action
mani
candid
vaccin
agent
fact
ration
design
vaccin
repres
drive
forc
born
first
revel
compon
relat
microbi
pathogen
use
protect
diseas
present
throughout
develop
vaccin
modern
era
hone
understand
prepar
way
next
step
battl
combat
today
signific
pathogen
diseas
cancer
hiv
tuberculosi
malaria
era
begin
explor
limit
immunotherapeut
prophylact
intervent
tool
develop
elucid
gene
express
function
might
last
begun
find
applic
signific
challeng
